Welcome to our dedicated page for Pharmather Holdings news (Ticker: PHRRF), a resource for investors and traders seeking the latest updates and insights on Pharmather Holdings stock.
PharmaTher Holdings Ltd. (OTCQB: PHRRF, CSE: PHRM) generates news centered on its ketamine-focused pharmaceutical programs, drug delivery platforms, and related asset monetization activities. Company announcements describe a specialty pharmaceutical and life sciences business focused on unlocking the pharmaceutical and therapeutic potential of ketamine, psychedelics, and GLP-1 drugs, particularly for neuropsychiatric, mental health, pain, neurological, and obesity-related disorders.
News updates cover several recurring themes. One major area is the development of ketamine-based therapies, including a program for levodopa-induced dyskinesia in Parkinson's disease (LID-PD) that the company is preparing to advance under the FDA 505(b)(2) pathway toward a Phase 3 strategy. Releases describe regulatory planning, prior Phase I/II data, intellectual property coverage, and discussions with potential pharmaceutical partners. Another frequent topic is the evolution of a long-acting injectable ketamine franchise under an exclusive evaluation and option-to-license agreement with Oakwood Laboratories, which is intended to address neuropsychiatric indications such as treatment-resistant depression and major depressive disorders.
PharmaTher also issues news about its PharmaPatch™ microneedle patch platform, including initiatives to deliver ketamine, psychedelic compounds, and GLP-1 drugs, and its expansion into GLP-1 therapies for the potential treatment of obesity. Additional updates highlight the Digital Health AI division, featuring KetaVault™ and KetAImine™, which are presented as ketamine data and AI discovery platforms designed to generate new indications and combination programs.
Corporate communications further report on the FDA-approved ketamine ANDA, its sale to a sterile-injectables partner with milestone and profit-sharing economics, and the company's broader asset strategy, including its 49% equity interest in Sairiyo Therapeutics Inc. Investors and observers who follow PHRRF news can use this page to review company statements on clinical plans, regulatory interactions, partnering discussions, and platform expansions as disclosed in official releases.
PharmaTher (OTCQB: PHRRF) says its PatchPrint™ automated microneedle manufacturing platform and PharmaPatch™ product platform could benefit from two U.S. regulatory shifts: a presidential executive order accelerating psychedelic treatments and an FDA/HHS move to reclassify therapeutic peptides with an advisory meeting on July 23–24, 2026.
The company highlights completed IND‑enabling work for a ketamine patch, provisional U.S. patent filings for peptide candidates and PatchPrint™, and potential commercial pathways for compounding pharmacies and hospitals.
PharmaTher (OTCQB: PHRRF) supports a proposed U.S. peptide reclassification and links the potential policy change to increased commercial relevance for its PharmaPatch microneedle delivery and PatchPrint manufacturing platform.
The company notes the FDA's July 23-24, 2026 Pharmacy Compounding Advisory Committee agenda lists BPC-157, KPV and TB-500—peptides already on PharmaTher's roadmap—and cites a provisional patent filed April 13, 2026 for stabilized peptide formulations for microneedle delivery.
PharmaTher (OTCQB: PHRRF) filed U.S. provisional patent application No. 64/034,315 on April 13, 2026 for "Stabilized Peptide Compositions for Microneedle and Transdermal Delivery." The filing aims to protect formulation approaches to improve peptide stability, shelf life, manufacturing compatibility and layered microneedle designs for PharmaPatch while complementing PatchPrint manufacturing.
Claims include polymers, sugars, amino acids, buffers, layered tip/backing designs, low-moisture packaging, and support for multiple peptide categories and combined-peptide dosage forms.
PharmaTher (OTCQB: PHRRF) filed a provisional USPTO patent (Application No. 64/015,408) on March 26, 2026 for PatchPrint, an automated tabletop microneedle patch 3D printer that integrates dispensing, vacuum loading, drying, demolding and packaging.
The company is pursuing commercialization, engineering partnerships, peptide patch development, branded wellness products and partner-facing manufacturing services to scale its PharmaPatch programs.
PharmaTher (OTCQB: PHRRF) announced a strategic initiative on March 3, 2026 to expand its PharmaPatch™ microneedle platform into select therapeutic peptides for the U.S. market.
The company cited prior ketamine, psychedelics and GLP-1 patch work, named initial candidates (BPC-157, GHK-Cu, TB-500, KPV), referenced a large U.S. peptide market (US$65.1B 2024 to ~US$160.3B by 2030, 14.7% CAGR), and noted staged R&D, regulatory monitoring, and investigational status with no FDA approvals.
PharmaTher (OTCQB: PHRRF) announced a strategic initiative to seek Health Canada approval for generic semaglutide and, if approved, commercialize in Canada. Regulatory exclusivity expired in January 2026, opening a pathway for generics. The plan targets Health Canada approval in 2026 with broad dose coverage (0.25 mg–2.4 mg) and a sterile injectable manufacturing strategy audited by regulators. The company cites prior U.S. FDA approval and monetization of ketamine rights with potential proceeds exceeding US$25 million, and notes Ozempic generated an estimated C$2.9 billion in Canadian sales in 2025.
PharmaTher (OTCQB: PHRRF) announced a strategic initiative to apply its PharmaPatch™ microneedle patch platform to GLP-1 therapies for obesity on January 14, 2026. The company cites prior pre-IND work and published research on ketamine and psychedelic patches to support controlled, sustained delivery and flexible dosing.
PharmaTher aims to develop a needle-free, at-home microneedle patch with potential delivery of up to one month from a single application, will pursue feasibility and preclinical studies, and expects to file a patent application later this month. The release highlights a cited U.S. obesity market forecast of $11.2B in 2024 rising to $48.5B by 2030.
PharmaTher (OTCQB: PHRRF) published a January 2, 2026 letter from CEO Fabio Chianelli outlining 2025 milestones and 2026 priorities. Key 2025 achievements included FDA approval of Ketamine ANDA #217858, the sale and December 2025 closing of that ANDA under a deal with upfronts, sales milestones and profit‑sharing potentially exceeding US$25 million, and reduced cash burn entering 2026.
For 2026 the company plans to: realize economics from the ANDA sale, pursue ex‑U.S. ketamine commercialization and partnerships (Parkinson's and drug delivery), evaluate a long‑acting injectable program via an Oakwood agreement, and crystallize value from its 49% equity interest in Sairiyo Therapeutics.
PharmaTher (OTCQB: PHRRF) closed the sale of its Ketamine Hydrochloride Injection ANDA #217858 to a sterile-injectables company on December 2, 2025, receiving a confidential upfront cash payment and remaining eligible for milestone and seven-year profit-sharing payments.
The transaction could generate more than US$25 million over time, subject to commercial performance, and frees PharmaTher to focus on its patented long-acting injectable (LAI) ketamine program with Oakwood Laboratories via an exclusive evaluation and option-to-license agreement.
PharmaTher (OTCQB: PHRRF) entered an Exclusive Evaluation and Option-to-License Agreement with Oakwood Laboratories to evaluate and potentially license a patented long-acting injectable (LAI) ketamine program on a 12-month exclusive evaluation term dated November 17, 2025.
The LAI program uses Oakwood's sustained-release microsphere platform for subcutaneous or intramuscular dosing, targets treatment-resistant depression (TRD), major depressive disorders and Parkinson's disease-related LID, and is planned to pursue a 505(b)(2) regulatory pathway. Management cites SPRAVATO® as a $1.64B TTM market reference and notes projected annual sales of $3.0–$3.5B by 2027–2028 for that market.
Near-term actions include finalizing CMC, engaging FDA on development strategy, and preparing for clinical studies to advance the program toward an option exercise and potential global license.